Mahmoud S Alghamri
Overview
Explore the profile of Mahmoud S Alghamri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
686
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Narayan P, Readler J, Alghamri M, Brockman T, Yan R, Sharma P, et al.
Pathogens
. 2022 Feb;
11(2).
PMID: 35215116
The coxsackievirus and adenovirus receptor (CAR) is an essential cellular protein that is involved in cell adhesion, cell signaling, and viral infection. The 8-exon encoded isoform (CAR) resides at the...
12.
Alghamri M, McClellan B, Avvari R, Thalla R, Carney S, Hartlage C, et al.
Sci Adv
. 2021 Sep;
7(40):eabh3243.
PMID: 34586841
Mutant isocitrate-dehydrogenase 1 () synthesizes the oncometabolite 2-hydroxyglutarate (2HG), which elicits epigenetic reprogramming of the glioma cells’ transcriptome by inhibiting DNA and histone demethylases. We show that the efficacy of...
13.
Shah D, Comba A, Faisal S, Kadiyala P, Baker G, Alghamri M, et al.
Oncoimmunology
. 2021 Jul;
10(1):1939601.
PMID: 34249474
Although pharmacological stimulation of TLRs has anti-tumor effects, it has not been determined whether endogenous stimulation of TLRs can lead to tumor rejection. Herein, we demonstrate the existence of an...
14.
Garcia-Fabiani M, Haase S, Comba A, Carney S, McClellan B, Banerjee K, et al.
Front Oncol
. 2021 Jun;
11:631037.
PMID: 34168976
High grade gliomas are malignant brain tumors that arise in the central nervous system, in patients of all ages. Currently, the standard of care, entailing surgery and chemo radiation, exhibits...
15.
Alghamri M, McClellan B, Hartlage C, Haase S, Faisal S, Thalla R, et al.
Front Pharmacol
. 2021 Jun;
12:680021.
PMID: 34084145
Gliomas are one of the most lethal types of cancers accounting for ∼80% of all central nervous system (CNS) primary malignancies. Among gliomas, glioblastomas (GBM) are the most aggressive, characterized...
16.
Banerjee K, Nunez F, Haase S, McClellan B, Faisal S, Carney S, et al.
Front Mol Neurosci
. 2021 Apr;
14:621831.
PMID: 33790740
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain barrier (BBB),...
17.
Alghamri M, Sharma P, Williamson T, Readler J, Yan R, Rider Jr S, et al.
J Virol
. 2021 Mar;
95(13):e0004621.
PMID: 33762416
Adenoviruses (AdVs) are etiological agents of gastrointestinal, heart, eye, and respiratory tract infections that can be lethal for immunosuppressed people. Many AdVs use the coxsackievirus and adenovirus receptor (CAR) as...
18.
Kadiyala P, Carney S, Gauss J, Garcia-Fabiani M, Haase S, Alghamri M, et al.
J Clin Invest
. 2020 Dec;
131(4).
PMID: 33332283
Mutant isocitrate dehydrogenase 1 (IDH1-R132H; mIDH1) is a hallmark of adult gliomas. Lower grade mIDH1 gliomas are classified into 2 molecular subgroups: 1p/19q codeletion/TERT-promoter mutations or inactivating mutations in α-thalassemia/mental...
19.
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
Alghamri M, Thalla R, Avvari R, Dabaja A, Taher A, Zhao L, et al.
Neurooncol Adv
. 2020 Jul;
2(1):vdaa042.
PMID: 32642696
Background: Gliomas are the most common primary brain tumors. High-Grade Gliomas have a median survival (MS) of 18 months, while Low-Grade Gliomas (LGGs) have an MS of approximately 7.3 years....
20.
Garcia-Fabiani M, Ventosa M, Comba A, Candolfi M, Nicola Candia A, Alghamri M, et al.
Expert Opin Investig Drugs
. 2020 May;
29(7):659-684.
PMID: 32400216
Introduction: Gliomas are infiltrating brain tumors associated with high morbidity and mortality. Current standard of care includes radiation, chemotherapy, and surgical resection. Today, survival rates for malignant glioma patients remain...